FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1649-1650 December 15, 1994 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Until the report earlier this year of more than 100 cases of hepatitis C virus infection in 24 states,¹ most U.S. physicians believed that intravenous immune globulin did not pose the risks of transmitting viral infections that have been associated with other blood products. Indeed, immune globulin has proved to be a very safe product, tens of millions of grams of which have been infused worldwide without serious problems. However, as the report by Bjoro et al.² in this issue of the Journal demonstrates, this outbreak of hepatitis C is not unique and serves as a reminder that all medical . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Brannagan, T. H. III (2002). Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 59: S33-40 [Abstract] [Full Text]  
• Pyne, D., Ehrenstein, M., Morris, V. (2002). The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology (Oxford) 41: 367-374 [Full Text]  
• Keller, M. A., Stiehm, E. R. (2000). Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin. Microbiol. Rev. 13: 602-614 [Abstract] [Full Text]  
• Kenny-Walsh, E., The Irish Hepatology Research Group, (1999). Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin. NEJM 340: 1228-1233 [Abstract] [Full Text]  
• Stadtmauer, G., Cunningham-Rundles, C. (1997). Outcome Analysis and Cost Assessment in Immunologic Disorders. JAMA 278: 2018-2023 [Abstract]  
• Francis, G. S, Freedman, M. S, Antel, J. P (1997). Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. Mult Scler 3: 370-376 [Abstract]  
• Ratko, T. A., Burnett, D. A., Foulke, G. E., Matuszewski, K. A., Sacher, R. A. (1995). Recommendations for Off-Label Use of Intravenously Administered Immunoglobulin Preparations. JAMA 273: 1865-1870 [Abstract]  
• Douglas, S. D., Slade, H. B., Lopez-Jimenez, J., Odriozola, J., Perez-Oteyza, J., Garcia-Larana, J., Prince, A. M., Horowitz, B., Bjoro, K., Froland, S. S., Schiff, R. I. (1995). Hepatitis C and Immune Globulin. NEJM 332: 1235-1237 [Full Text]